About
Technology
Issues
FAQ
Links
Official Page
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.